Literature DB >> 23052570

Effectiveness and tolerability of long-acting intramuscular risperidone as adjuvant treatment in refractory borderline personality disorder.

J L Carrasco, N Palomares, M Díaz Marsá.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23052570     DOI： 10.1007/s00213-012-2880-0

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN： 0033-3158            Impact factor:   4.530


× No keyword cloud information.
  4 in total

Review 1.  Pharmacological treatments for personality disorders.

Authors:  Joel Paris
Journal:  Int Rev Psychiatry       Date:  2011-06

2.  Personality disorder and suicide. A case-control study.

Authors:  A T Cheng; A H Mann; K A Chan
Journal:  Br J Psychiatry       Date:  1997-05       Impact factor: 9.319

3.  The process of managing medications in patients with borderline personality disorder.

Authors:  Kenneth R Silk
Journal:  J Psychiatr Pract       Date:  2011-09       Impact factor: 1.325

Review 4.  Recent advances in the treatment of borderline personality disorder.

Authors:  Joel Paris
Journal:  Can J Psychiatry       Date:  2005-07       Impact factor: 4.356
  4 in total
  4 in total

Review 1.  Pharmacotherapy for borderline personality disorder--current evidence and recent trends.

Authors:  Jutta M Stoffers; Klaus Lieb
Journal:  Curr Psychiatry Rep       Date:  2015-01       Impact factor: 5.285

2.  Long-Acting Injectable Antipsychotics: Analysis of Prescription Patterns and Patient Characteristics in Mental Health from a Spanish Real-World Study.

Authors:  Juan Antonio García-Carmona; Jorge Simal-Aguado; María Pilar Campos-Navarro; Francisco Valdivia-Muñoz; Alejandro Galindo-Tovar
Journal:  Clin Drug Investig       Date:  2020-05       Impact factor: 2.859

Review 3.  Patients with Borderline Personality Disorder in Emergency Departments.

Authors:  Untara Shaikh; Iqra Qamar; Farhana Jafry; Mudasar Hassan; Shanila Shagufta; Yassar Islamail Odhejo; Saeed Ahmed
Journal:  Front Psychiatry       Date:  2017-08-04       Impact factor: 4.157

4.  Second-generation antipsychotic use in borderline personality disorder: What are we targeting?

Authors:  Adrian Wasylyshen; Andrew M Williams
Journal:  Ment Health Clin       Date:  2016-03-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.